Friday , September 30 2022

Roche receives US approval for Xofluza flu drug in the form of another dose | 11/23/20


Basel (awp) – Roche’s subsidiary Genentech is allowed to sell the flu drug Xofluza in the U.S. in the form of another dose. It can now also be sold as water-soluble particles, as the FDA announced Monday. Until now, Xofluza was only available in tablet form.

Xofluza (Baloxavir-Marboxil) was first approved in the US in 2018. The antiviral drug is used to treat and prevent flu.

This approval is important because the flu season will not be like any other because of the corona pandemic, which is rampant at the same time, the notification from the approving authority continues.

rw /

Source link